Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Key Takeways U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Leerink notes Eli Lilly’s (LLY) once-daily oral GLP-1 pill showed similar efficacy and safety relative to weekly injectable semaglutide, made ...

BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in the obesity drug market is ...

Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...

Novo Nordisk A/S (NYSE:NVO) shares fell as much as 8% in Thursday trading after news emerged about a competitor's successful drug trial. Eli Lilly and Company (NYSE:LLY) announced today that its ...